Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma

Gynecologic Oncology

Volumn 128, Issue 2, 2013, Pages 221-228

  Tillmanns, Todd D ^a   Lowe, M Patrick ^b,d   Walker, Mark S ^c   Stepanski, Edward J ^c   Schwartzberg, Lee S ^a  

^a WEST CLINIC   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ACORN Research LLC   (United States)

^d ADVOCATE CHRIST MEDICAL CENTER   (United States)

Author keywords

Albumin bound paclitaxel; Bevacizumab; Epithelial ovarian cancer; Platinum resistant; Primary peritoneal cancer; Toxicities

Indexed keywords

ALBUMIN; ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; CREATININE; PACLITAXEL;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ASCITES; BODY TEMPERATURE; BRONCHITIS; CANCER SURVIVAL; CANDIDIASIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLITIS; CONFERENCE PAPER; CONSTIPATION; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; INFECTION; LEUKOCYTE COUNT; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NIGHTMARE; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PERIPHERAL EDEMA; PERITONEUM TUMOR; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIMARY EPITHELIAL OVARY CARCINOMA; PRIMARY PERITONEAL CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84872835463     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.08.039     Document Type: Conference Paper

References (38)

1. B.A. Goff, L.S. Mandel, C.H. Melancon, and H.G. Muntz Frequency of symptoms of ovarian cancer in women presenting to primary care clinics JAMA 291 2004 2705 2712 (Pubitemid 38725419)
2. American Cancer Society Cancer facts and figures 2011 2011 American Cancer Society Atlanta GA
3. M.K. Parmar, J.A. Ledermann, N. Colombo, A. du Bois, J.F. Delaloye, and G.B. Kristensen Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2099 2106
4. J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, and A.J. Lacave Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 2006 4699 4707 (Pubitemid 46630933)
5. F.M. Muggia, J.D. Hainsworth, S. Jeffers, P. Miller, S. Groshen, and M. Tan Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation J Clin Oncol 15 1997 987 993 (Pubitemid 27106281)
6. J. Sehouli, D. Stengel, P. Harter, C. Kurzeder, A. Belau, and T. Bogenrieder Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter Phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group J Clin Oncol 2010
7. P.G. Rose, J.A. Blessing, A.R. Mayer, and H.D. Homesley Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study J Clin Oncol 16 1998 405 410 (Pubitemid 28135580)
8. M. Markman, K. Webster, K. Zanotti, B. Kulp, G. Peterson, and J. Belinson Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer Gynecol Oncol 90 2003 593 596
9. P.G. Rose, J.A. Blessing, H.G. Ball, J. Hoffman, D. Warshal, and K. DeGeest A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 88 2003 130 135 (Pubitemid 36263370)
10. E.S. Han, R.A. Burger, K.M. Darcy, M.W. Sill, L.M. Randall, and D. Chase Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer Gynecol Oncol 119 2010 484 490
11. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171 (Pubitemid 350237599)
12. R.A. Burger, M.F. Brady, M.A. Bookman, J.L. Walker, H.D. Homesley, and J. Fowler Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): a Gynecologic Oncology Group study Journal of Clinical Oncology 2010 American Society of Clinical Oncology Chicago, IL 946s
13. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, and L. Roman Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 2008 76 82
14. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186 (Pubitemid 350232248)
15. J.D. Wright, A. Hagemann, J.S. Rader, D. Viviano, R.K. Gibb, and L. Norris Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis Cancer 107 2006 83 89 (Pubitemid 43939034)
16. J.C. Chura, K. Van Iseghem, L.S. Downs Jr., L.F. Carson, and P.L. Judson Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer Gynecol Oncol 107 2007 326 330 (Pubitemid 47575735)
17. H.S. Nimeiri, A.M. Oza, R.J. Morgan, G. Friberg, K. Kasza, and L. Faoro Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia Gynecol Oncol 110 2008 49 55
18. B.J. Monk, E. Han, C.A. Josephs-Cowan, G. Pugmire, and R.A. Burger Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer Gynecol Oncol 102 2006 140 144 (Pubitemid 44056265)
19. F. Simpkins, J.L. Belinson, and P.G. Rose Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening Gynecol Oncol 107 2007 118 123 (Pubitemid 47464553)
20. V. Ranpura, B. Pulipati, D. Chu, X. Zhu, and S. Wu Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis Am J Hypertens 23 2010 460 468
21. J.P. Diaz, W.P. Tew, O. Zivanovic, J. Konner, P.J. Sabbatini, and L.A. dos Santos Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma Gynecol Oncol 116 2010 335 339
22. G.P. Sfakianos, T.M. Numnum, C.B. Halverson, D. Panjeti, Kendrick JEt, and J.M. Straughn Jr. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study Gynecol Oncol 114 2009 424 426
23. A.V. Hoekstra, J.A. Hurteau, C.V. Kirschner, and G.C. Rodriguez The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer Gynecol Oncol 115 2009 377 381
24. D.M. O'Malley, D.L. Richardson, P.S. Rheaume, R. Salani, E.L. Eisenhauer, and G.A. McCann Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer Gynecol Oncol 121 2011 269 272
25. M.G. Teneriello, P.C. Tseng, M. Crozier, C. Encarnacion, K. Hancock, and M.J. Messing Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer J Clin Oncol 27 2009 1426 1431
26. R.L. Coleman, W.E. Brady, D.S. McMeekin, P.G. Rose, J.T. Soper, and S.S. Lentz A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study Gynecol Oncol 122 2011 111 115
27. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, and E.T. McFadden Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655 (Pubitemid 13149996)
28. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 2003 [Washington, D.C.]
29. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
30. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
31. M. Greenwood The natural duration of cancer Reports on public health and medical subjects 1926 Her Majesty's Stationery Office London 1 26
32. R.A. Burger Overview of anti-angiogenic agents in development for ovarian cancer Gynecol Oncol 121 2011 230 238
33. R. Burger, M. Brady, M. Bookman, B. Monk, J. Walker, and H. Homesley Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: a Gynecologic Oncology Group study 2010 Society of Gynecological Oncology Orlando, FL
34. N. Katsumata, M. Yasuda, F. Takahashi, S. Isonishi, T. Jobo, and D. Aoki Japanese gynecologic oncology G. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 1331 1338
35. A. Lortholary, R. Largillier, B. Weber, L. Gladieff, J. Alexandre, and X. Durando Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) Ann Oncol 23 2012 346 352
36. G. Dranitsaris, R. Coleman, and W. Gradishar nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial Breast Cancer Res Treat 119 2010 717 724
37. M. Markman The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapy Cancer 117 2011 660 661
38. T.D. Tillmanns, M.P. Lowe, L.S. Schwartzberg, M.S. Walker, and E.J. Stepanski A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma ASCO Meeting Abstracts 28 2010 5009